-
An antibiotic, Ketek, had side effects and multiple problems with its clinical trials, including outright fraud.
FORBES: Why Presidents Don't Shape The FDA
-
And Ketek is too big for bacteria to simple bilge it away.
FORBES: FDA OKs Aventis Antibiotic
-
To fix these problems, Ketek grapples onto a second spot inside the bacteria, so bacteria can no longer escape the drug with a single mutation.
FORBES: Antibiotic Breakthroughs Fall Short
-
Abbott was developing a drug similar to Ketek, but it was put on the back burner so the company could focus on other, more promising leads.
FORBES: Antibiotic Breakthroughs Fall Short
-
Still, the long delay could put a damper on Ketek sales.
FORBES: FDA OKs Aventis Antibiotic
-
To fix these problems, Ketek grapples onto a second spot inside the bacteria, so the bugs can no longer escape the drug with a single mutation.
FORBES: FDA OKs Aventis Antibiotic
-
Wyeth's Tygacil and Sanofi-Aventis ' Ketek have been touted as new classes, and though the distinction can be argued, both were definitely better at fighting resistant bugs.
FORBES: Magazine Article
-
Aventis' pill, Ketek, does represent a significant advance, but some doctors argue that it isn't that new, and some stock analysts fear that labeling issues could cut the drug's sales.
FORBES: Antibiotic Breakthroughs Fall Short
-
Ketek could provide doctors with a powerful new option.
FORBES: FDA OKs Aventis Antibiotic
-
For medicines ranging from Pfizer's antipsychotic Geodon to Ketek, an antibiotic from Sanofi-Aventis (nyse: SNY - news - people ), such problems have led to regulatory delays--although both were eventually approved.
FORBES: A Biotech's Big Comeback
-
But that was before Vioxx (withdrawn because of heart attacks) and Ketek (severely restricted because of liver side effects) and a series of other controversies that resulted in FDA brass being called in front of Congress.
FORBES: Biotech Busts And Breakthroughs In December
-
Ketek is a modified version of a commonly used class of antibiotics, called macrolides, which includes Pfizer 's (nyse: PFE - news - people ) Zithromax and Abbott Laboratories ' (nyse: ABT - news - people ) Biaxin.
FORBES: Antibiotic Breakthroughs Fall Short